October 4th 2019
Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
High Risks, High Costs Associated With Febrile Neutropenia in Metastatic Cancer
February 4th 2016Data from 2 large studies of patients with metastatic disease who underwent myelosuppressive chemotherapy found that febrile neutropenia occurred in approximately 13% to 21% of patients. Associated costs of febrile neutropenia were found to range from $16,000 to $19,000 per episode for most hospitalized patients.
Read More
Comparing Tbo-Filgrastim With Filgrastim During Neutrophil Engraftment
January 30th 2016A study comparing the efficacy of tbo-filgrastim with filgrastim when used to mobilize peripheral blood stem cells or to accelerate engraftment after autologous stem cell transplantation found no clinically meaningful differences, plus tbo-filgrastim saved money.
Read More